Cerus (CERS) to Release Quarterly Earnings on Thursday

Cerus (NASDAQ:CERS) is expected to issue its Q1 2025 quarterly earnings data after the market closes on Thursday, May 1st. Analysts expect Cerus to post earnings of ($0.05) per share and revenue of $47.44 million for the quarter.

Cerus (NASDAQ:CERS) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting the consensus estimate of ($0.01). Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. The business had revenue of $50.81 million for the quarter, compared to the consensus estimate of $50.81 million. On average, analysts expect Cerus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cerus Stock Up 1.5 %

Shares of CERS opened at $1.36 on Wednesday. The stock has a 50 day moving average price of $1.43 and a 200 day moving average price of $1.64. Cerus has a one year low of $1.12 and a one year high of $2.54. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.59. The stock has a market capitalization of $259.98 million, a price-to-earnings ratio of -12.36 and a beta of 1.70.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $4.00 target price on shares of Cerus in a research report on Friday, February 21st.

Insiders Place Their Bets

In other news, insider Richard J. Benjamin sold 51,254 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $1.58, for a total value of $80,981.32. Following the completion of the sale, the insider now owns 400,665 shares of the company’s stock, valued at $633,050.70. This represents a 11.34 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Kevin Dennis Green sold 60,656 shares of Cerus stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $1.58, for a total transaction of $95,836.48. Following the sale, the chief financial officer now directly owns 493,862 shares in the company, valued at approximately $780,301.96. The trade was a 10.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 441,150 shares of company stock valued at $665,210 in the last ninety days. 3.40% of the stock is currently owned by corporate insiders.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.